Bio-rad Laboratories, INC Form 4 insider transactions

James Barry, EVP and President of Life Science Group at Bio-Rad Laboratories, reports the acquisition of 4,224 restricted stock units.

Michael Crowley, EVP at Bio-Rad Laboratories, reports acquisition of restricted stock units.

Gregory K. Hinckley, a director at Bio-Rad Laboratories, reported the acquisition of 308 Restricted Stock Units (RSUs) on September 6, 2024.

Director Arnold A. Pinkston acquired 308 restricted stock units in Bio-Rad Laboratories, Inc. on September 6, 2024.

Melinda Litherland Pei, a director at Bio-Rad Laboratories, reported the acquisition of 308 restricted stock units (RSUs) on September 6, 2024, according to a Form 4 filing with the SEC.

Jeffrey L. Edwards, a director at Bio-Rad Laboratories, acquired 308 restricted stock units on September 6, 2024, which will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

EVP Michael Crowley reports the acquisition of Bio-Rad Class A common stock through vesting of restricted stock units and subsequent disposal to cover tax obligations.

Norman Schwartz, CEO of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.

Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported multiple transactions involving Bio-Rad A Common Stock, including acquisitions from restricted stock unit vesting and disposals to cover tax obligations.

James Barry, EVP and President of Life Science Group at Bio-Rad Laboratories, reports multiple transactions involving Bio-Rad Class A common stock, including acquisitions from restricted stock unit vesting and sales on the open market.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.

Director Allison Schwartz reports acquisition and disposal of Bio-Rad Laboratories Class A common stock related to vesting of restricted stock units.

Director Allison Schwartz reports receiving 57 shares of Bio-Rad B Common Stock on August 26, 2024.

Steven Schwartz, a director at Bio-Rad Laboratories, filed a Form 4 detailing changes in his beneficial ownership of company stock due to gift transactions.

Norman Schwartz, CEO of Bio-Rad Laboratories, reports a change in his beneficial ownership of company stock due to a gift.

Alice N. Schwartz, a Director Emeritus at Bio-Rad Laboratories, filed a Form 4 detailing changes in her beneficial ownership of the company's stock due to a gift.

Eva Anette Engelhardt, EVP and President of CDG at Bio-Rad Laboratories, acquired 983 restricted stock units on July 25, 2024, vesting over four years.

Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, sold 369 shares of Bio-Rad A Common Stock at a price of $281.9064 on June 13, 2024.

Director Steven Schwartz reported selling 320 shares of Bio-Rad Laboratories Class A common stock at $463.86 per share on May 3, 2023.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent tax withholding.

Roop Kalyan Lakkaraju, EVP and CFO of Bio-Rad Laboratories, reports the acquisition of 4,311 restricted stock units.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 744 restricted stock units on April 24, 2024, which vest over four years.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, acquired 5,891 non-qualified stock options on March 8, 2024.

Simon May, EVP and President of Life Science Group at Bio-Rad Laboratories, acquired 3,535 non-qualified stock options on March 8, 2024.

EVP of Global Human Resources at Bio-Rad Laboratories, Colleen Corey, reports the acquisition of stock options.

Timothy S. Ernst, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 2,357 non-qualified stock options on March 8, 2024.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reports acquisition of shares through employee stock purchase plan and grant of stock options.

Norman Schwartz, CEO of Bio-Rad Laboratories, reports the acquisition of stock options and changes in beneficial ownership of Bio-Rad common stock.

Michael Crowley, EVP at Bio-Rad Laboratories, reports acquisition of stock options.

EVP, General Counsel & Secretary of Bio-Rad Laboratories, Timothy S. Ernst, reports the exercise of stock options and subsequent sale of shares on February 28, 2024.